Its first COVID-19 vaccine failed last year, but fueled by payments from the EU, Germany and GSK, CureVac is trying again with two further versions of its mRNA platform.
CureVac is currently Germany’s other less successful mRNA vaccines company compared with BioNTech, but hopes to change that with a second and third attempt at the technology.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
